 5. HT2A receptor, 5. HT2AR, agonists have shown promise in combating opioid use disorder, OUD, but there is a need for preclinical profiling and further analysis of non-hallucinogenic 5. HT2AR agonists or positive allosteric modulators to ensure safety and efficacy. This article was authored by Leah M. Solinski, Christina Armaret, Joshua C. Samora, and others.